SCHEMBL2698015

SCHEMBL2698015

CC(C)(C)c1cc(-c2ccc(F)cc2)c(F)cc1N

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.41
HDAC2 Q92769 4/20 0.41
PTGS2 P35354 6/20 0.37
PTGS1 P23219 3/20 0.37
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALDH1A1 P00352 1/20 0.35
TDO2 P48775 1/20 0.35
SQOR Q9Y6N5 1/20 0.35
GCGR P47871 1/20 0.34
PIK3CA P42336 1/20 0.33
CFTR P13569 2/20 0.33
AKR1C3 P42330 1/20 0.33
AKR1C2 P52895 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9910015 0.85 MEN1 (0.38) PTGS2PTGS1KDM4EMEN1NPC1
SCHEMBL2696067 0.81 SQOR (0.43) PTGS2PTGS1KDM4EMEN1MAPT
SCHEMBL278779 0.77 PGR (0.42) HDAC1HDAC2PTGS2PTGS1MEN1
SCHEMBL24202659 0.72 HDAC1 (0.53) HDAC1HDAC2PTGS2PTGS1KDM4E
SCHEMBL14443262 0.71 ALDH1A1 (0.44) HDAC1PTGS2PTGS1MEN1MAPT
SCHEMBL279009 0.71 ALDH1A1 (0.50) HDAC1PTGS2PTGS1KDM4EMEN1
SCHEMBL10064808 0.69 GCGR (0.46) PTGS2PTGS1MEN1NPC1MAPT
SCHEMBL15853177 0.69 ACLY (0.40) PTGS2PTGS1MEN1MAPTKMT2A
SCHEMBL26262672 0.69 APP (0.51) PTGS2MEN1NPC1MAPTRAB9A
SCHEMBL1480584 0.69 PTGS2 (0.38) PTGS2PTGS1MAPTSQORGCGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088771-B2 Cycloalkylidene and heterocycloalkylidene inhibitor compounds GILEAD SCIENCES, INC. (US) 2012-01-03 US disclosed
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS GILEAD SCIENCES, INC. 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022543-A1 CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS HDAC1, HDAC11, HDAC2 HDAC1 1/4885HDAC2 3/4885PTGS2 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.